Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein

被引:31
作者
Bates, John T. [1 ,2 ]
Keefer, Christopher J. [2 ,3 ,4 ]
Slaughter, James C. [5 ,6 ]
Kulp, Daniel W. [7 ,8 ]
Schief, William R. [7 ,8 ,9 ]
Crowe, James E., Jr. [1 ,2 ,3 ,4 ]
机构
[1] Vanderbilt Univ, Med Ctr, Dept Microbiol, Vanderbilt Vaccine Ctr, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Med Ctr, Dept Immunol, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Med Ctr, Dept Pediat, Vanderbilt Vaccine Ctr, Nashville, TN 37232 USA
[4] Vanderbilt Univ, Med Ctr, Dept Microbiol, Nashville, TN 37232 USA
[5] Vanderbilt Univ, Med Ctr, Dept Biostat, Vanderbilt Vaccine Ctr, Nashville, TN 37232 USA
[6] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA
[7] Scripps Res Inst, IAVI Neutralizing Antibody Ctr, La Jolla, CA 92037 USA
[8] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA
[9] Scripps Res Inst, Ctr HIV AIDS Vaccine Immunol & Immunogen Discover, La Jolla, CA 92037 USA
关键词
Human; Antibodies; Monoclonal; Viral; Respiratory Syncytial Virus; Neutralizing; Palivizumab; F-GLYCOPROTEIN; COTTON RATS; INFECTION; MUTANTS; MOTAVIZUMAB; RESISTANT; PROPHYLAXIS; PREVENTION; MUTATIONS; EPITOPES;
D O I
10.1016/j.virol.2014.02.010
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The role of binding kinetics in determining neutralizing potency for antiviral antibodies is poorly understood. While it is believed that increased steady-state affinity correlates positively with increased virus-neutralizing activity, the relationship between association or dissociation rate and neutralization potency is unclear. We investigated the effect of naturally-occurring antibody resistance mutations in the RSV F protein on the kinetics of binding to palivizumab. Escape from palivizumab-mediated neutralization of RSV occurred with reduced association rate (K-on) for binding to RSV F protein, while alteration of dissociation rate (K-off) did not significantly affect neutralizing activity. Interestingly, linkage of reduced Km, with reduced potency mirrored the effect of increased K-on found in a high-affinity enhanced potency palivizumab variant (motavizumab). These data suggest that association rate is the dominant factor driving neutralization potency for antibodies to RSV F protein antigenic site A and determines the potency of antibody somatic variants or efficiency of escape of viral glycoprotein variants. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:139 / 144
页数:6
相关论文
共 28 条
[1]   Palivizumab-Resistant Human Respiratory Syncytial Virus Infection in Infancy [J].
Adams, Ortwin ;
Bonzel, Linda ;
Kovacevic, Alexander ;
Mayatepek, Ertan ;
Hoehn, Thomas ;
Vogel, Markus .
CLINICAL INFECTIOUS DISEASES, 2010, 51 (02) :185-188
[2]   Human Rotavirus VP6-Specific Antibodies Mediate Intracellular Neutralization by Binding to a Quaternary Structure in the Transcriptional Pore [J].
Aiyegbo, Mohammed S. ;
Sapparapu, Gopal ;
Spiller, Benjamin W. ;
Eli, Ilyas M. ;
Williams, Dewight R. ;
Kim, Robert ;
Lee, David E. ;
Liu, Tong ;
Li, Sheng ;
Woods, Virgil L., Jr. ;
Nannemann, David P. ;
Meiler, Jens ;
Stewart, Phoebe L. ;
Crowe, James E., Jr. .
PLOS ONE, 2013, 8 (05)
[3]   Reversion of Somatic Mutations of the Respiratory Syncytial Virus-Specific Human Monoclonal Antibody Fab19 Reveal a Direct Relationship between Association Rate and Neutralizing Potency [J].
Bates, John T. ;
Keefer, Christopher J. ;
Utley, Thomas J. ;
Correia, Bruno E. ;
Schief, William R. ;
Crowe, James E., Jr. .
JOURNAL OF IMMUNOLOGY, 2013, 190 (07) :3732-3739
[4]   NEUTRALIZATION EPITOPES OF THE F-GLYCOPROTEIN OF RESPIRATORY SYNCYTIAL VIRUS - EFFECT OF MUTATION UPON FUSION FUNCTION [J].
BEELER, JA ;
COELINGH, KV .
JOURNAL OF VIROLOGY, 1989, 63 (07) :2941-2950
[5]   The transmembrane domain of the respiratory syncytial virus F protein is an orientation-independent apical plasma membrane sorting sequence [J].
Brock, SC ;
Heck, JM ;
McGraw, PA ;
Crowe, JE .
JOURNAL OF VIROLOGY, 2005, 79 (19) :12528-12535
[6]   Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody Fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein [J].
Crowe, JE ;
Firestone, CY ;
Crim, R ;
Beeler, JA ;
Coelingh, KL ;
Barbas, CF ;
Burton, DR ;
Chanock, RM ;
Murphy, BR .
VIROLOGY, 1998, 252 (02) :373-375
[7]   Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants [J].
DeVincenzo, JP ;
Hall, CB ;
Kimberlin, DW ;
Sánchez, PJ ;
Rodriguez, WJ ;
Jantausch, BA ;
Corey, L ;
Kahn, JS ;
Englund, JA ;
Suzich, JA ;
Palmer-Hill, FJ ;
Branco, L ;
Johnson, S ;
Patel, NK ;
Piazza, FM .
JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (05) :975-978
[8]   Respiratory syncytial virus infection in elderly and high-risk adults [J].
Falsey, AR ;
Hennessey, PA ;
Formica, MA ;
Cox, C ;
Walsh, EE .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) :1749-1759
[9]   Prevention of respiratory syncytial virus infections in high-risk infantsby monoclonal antibody (palivizumab) [J].
Groothuis, JR ;
Nishida, H .
PEDIATRICS INTERNATIONAL, 2002, 44 (03) :235-241
[10]   RESPIRATORY-SYNCYTIAL-VIRUS INFECTIONS, RE-INFECTIONS AND IMMUNITY - PROSPECTIVE, LONGITUDINAL-STUDY IN YOUNG-CHILDREN [J].
HENDERSON, FW ;
COLLIER, AM ;
CLYDE, WA ;
DENNY, FW .
NEW ENGLAND JOURNAL OF MEDICINE, 1979, 300 (10) :530-534